AI Article Synopsis
- - An estimated 1 in 200 newborns in the US are affected by congenital cytomegalovirus (cCMV), which can lead to hearing loss and neurological issues if not identified quickly.
- - Timely detection of cCMV through newborn screening allows for better diagnosis and management of its effects, reducing the risk of misdiagnosis and future complications.
- - Key health organizations advocate for universal newborn cCMV screening to improve health outcomes and provide proper intervention for affected infants.
Article Abstract
It is estimated that 1 in every 200 US newborns has congenital cytomegalovirus (cCMV). Delayed identification of cCMV in newborns precludes timely intervention to mitigate sequelae of the infection such as hearing loss and other neurological complications. Newborn testing for cCMV enables appropriate diagnosis and intervention by multidisciplinary teams to properly manage the immediate sequelae of cCMV, avoid unnecessary additional testing that can result from delayed diagnosis, and monitor for future complications. It is the position of the American Cochlear Implant Alliance, the National CMV Foundation, and the American Academy of Otolaryngology-Head and Neck Surgery that universal newborn cCMV screening is necessary to best accomplish these goals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ohn.1079 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!